Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ISB 1442 for relapsed/refractory multiple myeloma
ACTRN12622000856718Phase 2Not yet recruiting
- Sponsor
- Ichnos Sciences Inc.
- Start
- Jul 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label trial of ISB 1442 in multiple myeloma (MM) (9 cohorts), sponsored by Ichnos Sciences Inc. Primary endpoints: Safety and tolerability, Maximum tolerated dose and/or recommended phase 2 dose and 1 more. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
ISB 1442
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ACTRN12622000856718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12622000856718.